**1. Introduction**

Initially recognised in ancient Greece as a pig disease, neurocysticercosis is the most prevalent helminthic disease of the human CNS. The majority of the developing world is affected by the disease, which thrives in environments with a warm climate, extreme deprivation, and widespread illiteracy. The disease is a health concern in metropolitan areas of developing countries because neurocysticercosis is a significant contributor [1–3]. In the industrialised world, the prevalence of neurocysticercosis has grown along with the number of immigrants coming from endemic countries. Latin American immigrants account for approximately 90% of neurocysticercosis patients in the United States and Europe [4–6]. However, neurocysticercosis has also been seen in people who have never travelled to a location where it is endemic. The majority of these people become ill after being exposed to an adult *T. solium* in their bowel [7]. The host's immunological response to the cysticerci pleomorphic lesions

that parasites generate in the body is sporadic, and the condition is intriguing because it affects the CNS. Neurocysticercosis has sparked a great deal of interest due to medications. Here, we'll go over the key elements of this emphasis on the pathogenesis of parasitic diseases, and on current developments in diagnosis and treatment.
